Có ông ngoại cũng không được

As Covid-19 started spreading in Wuhan early last year, Chinese billionaire (tỷ phú) Guo Guangchang’s drugmaker (sản xuất dược) appeared to have scored a big win: A partnership with Germany’s BioNTech SE, which went on to produce with Pfizer Inc. one of the world’s most successful vaccines against the coronavirus.

Yet almost a year later, the shot is yet to be approved (phê duyệt) in mainland China, and in recent weeks Beijing has thrown its heft behind a homegrown mRNA vaccine, allowing China’s Walvax Biotechnology Co. to test its own experimental shot as a booster. The developments are raising new questions about whether the U.S.-German vaccine, licensed for the potentially lucrative (có lợi lộc) Greater China region by Guo’s Shanghai Fosun Pharmaceutical Group Co., will ever be used on the mainland, where President Xi Jinping’s administration has backed a nationalist (dân tộc chủ nghĩa) agenda on all fronts (mặt trận), including in the fight against the virus.

Bài trước: Trung Quốc chấm dứt bản quyền độc quyền âm nhạc